The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B
BackgroundFunctional cure rates in chronic hepatitis B (CHB) remain below 10% after long-term nucleos(t)ide analogue (NA) therapy, and PD-1/PD-L1 blockade achieves HBsAg clearance in approximately 30% of selected patients with low baseline HBsAg (≤100 …